| Rank |
Status |
Study |
| 1 |
Unknown †
|
Does Oral Sildenafil (Viagra) Decrease Mean Pulmonary Artery Pressure After Cardiac Surgery?
| Condition: |
Pulmonary Hypertension |
| Interventions: |
Drug: Sildenafil (Viagra); Drug: Sildenafil; Drug: Placebo |
| Outcome Measures: |
To determine the efficacy of 12.5mg oral sildenafil to decrease the mPAP in patients presenting with a mPAP >/= 25mmHg after cardiopulmonary bypass.; To determine the efficacy of a second dose of oral sildenafil 12.5mg to decrease the mPAP in those patients who do not respond with a 20% decrease in mPAP after the initial administration of study medication.; To determine the safety of oral sildenafil to treat increased mPAP after cardiac surgery. |
|
| 2 |
Unknown †
|
Sildenafil for Prevention of Cerebral Vasospasm
| Conditions: |
Subarachnoid Hemorrhage; Cerebral Vasospasm; Rupture of Intracranial Aneurysm |
| Interventions: |
Drug: Placebo; Drug: Sildenafil Citrate, 25 mg, 3 times a day.; Drug: Sildenafil Citrate 50 mg, 3 times a day |
| Outcome Measures: |
New neurological Deficit; Transcranial Ecodoppler; Mortality; Side effects; Time to discharge; Rankin Scale |
|
| 3 |
Unknown †
|
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
| Condition: |
Erectile Dysfunction |
| Interventions: |
Drug: Sildenafil Citrate 20mg Tablet Sublingual; Drug: Viagra ® 50mg tablet Coated |
| Outcome Measures: |
Evaluate a possible superiority expressed by the faster onset of action.; Evaluate the efficacy and tolerability of Sildenafil Citrate 20mg Sublingual tablet, compared to Viagra ® 50mg tablet Coated in control of Erectile Dysfunction. |
|
| 4 |
Recruiting
|
Pharmacokinetics of Sildenafil in Premature Infants
| Condition: |
Persistent Pulmonary Hypertension of the Newborn |
| Intervention: |
Drug: 1 dose of sildenafil |
| Outcome Measures: |
Area under the plasma concentration versus time curve 0-24 hours for sildenafil; Peak plasma concentration of sildenafil; Clearance of sildenafil; Volume of distribution at steady state; Half life of sildenafil; Number of subjects with adverse events as a measure of safety and tolerability.; Correlation between serum and dried blood spot samples; Evaluate P450 single nucleotide polymorphisms (SNPs) |
|
| 5 |
Unknown †
|
Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS
| Condition: |
Chronic Fatigue Syndrome |
| Interventions: |
Drug: Sildenafil (Viagra); Drug: Placebo |
| Outcome Measure: |
The principal aim of this study is to determine whether chronic fatigue syndrome (CFS) is due to inadequate blood flow to the brain and to test a medication, Viagra, which should help increase blood flow to the brain and improve the symptoms of CFS. |
|
| 6 |
Unknown †
|
Effects of Viagra on Heart Function in Patients With Heart Failure
| Conditions: |
Heart Failure; Left Ventricular Dysfunction |
| Intervention: |
Drug: sildenafil |
| Outcome Measures: |
The primary outcome measure is a fall in the left ventricular filling pressure in association with administration of sildenafil; A secondary outcome is the distance walked with the 6-minute walk test after the administration of sildenafil |
|
| 7 |
Not yet recruiting
|
Effects of Oral Sildenafil on Mortality in Adults With PAH
| Condition: |
Pulmonary Arterial Hypertension |
| Intervention: |
Drug: sildenafil citrate |
| Outcome Measures: |
Overall Survival (OS); Time to first clinical worsening (TTCW) event; 6 Minute Walk Distance (6MWD) at Months 6 & 12 |
|
| 8 |
Recruiting
|
VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension
| Condition: |
Pulmonary Hypertension Associated With Connective Tissue Disease |
| Intervention: |
Drug: Sildenafil |
| Outcome Measures: |
efficacy of Sildenafil I.V. for vasoreactivity testing; clinical efficacy of sildenafil per os predicted by testing it intravenously in the course of oral therapy |
|
| 9 |
Unknown †
|
Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy
| Condition: |
Prostate Cancer |
| Intervention: |
Drug: sildenafil 100mg |
| Outcome Measures: |
patterns of recovery of erectile functions after nerve sparing RALP in men with on- demand sildenafil 100mg dosing from the early postoperative period (using IIEF-5); comparison of the potency rates in men with on- demand sildenafil 100mg dosing from the early postoperative period with from the delayed postoperative period |
|
| 10 |
Unknown †
|
Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure
| Condition: |
Heart Failure |
| Intervention: |
Drug: Sildenafil |
| Outcome Measures: |
Change in 6-minute walk distance; Changes in peak oxygen consumption (measured by cardiopulmonary exercise testing); Change in the level of neurohormones (b-type natriuretic peptide, catecholamines, ET-1),; Change in quality of life |
|
| 11 |
Unknown †
|
The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation
| Condition: |
Fontan Circulation |
| Interventions: |
Drug: sildenafil; Other: placebo |
| Outcome Measure: |
An increase in exercise capacity for patients administered sildenafil |
|
| 12 |
Recruiting
|
The Revaki-001. A Study to Determine the Pharmacokinetic Profile, Safety and Tolerability of Sildenafil (REVATIO®) in Cardiac Surgery
| Condition: |
Acute Kidney Injury |
| Intervention: |
Drug: Sildenafil |
| Outcome Measures: |
Area under the plasma concentration versus time curve and Plasma Concentration of Sildenafil; Serum creatinine and Biochemical markers of AKI |
|
| 13 |
Recruiting
|
Effects of Sildenafil on Choroidal Thickness in AMD
| Condition: |
Age-related Macular Degeneration |
| Intervention: |
Drug: Sildenafil citrate |
| Outcome Measures: |
Change in Choroidal Thickness as Assessed on Enhanced-Depth Imaging Optical Coherence Tomography (EDI-OCT); Change in Central Foveal Thickness as assessed by optical coherence tomography (OCT) |
|
| 14 |
Unknown †
|
Viagra for the Treatment of IUGR
| Condition: |
IUGR |
| Intervention: |
Drug: Viagra administration in IUGR/PET pregnancies |
| Outcome Measures: |
Uteroplacental perfusion; Fetal growth; Maternal and fetal safety |
|
| 15 |
Not yet recruiting
|
Blood Flow and Vascular Function in Cystic Fibrosis
| Condition: |
Cystic Fibrosis |
| Interventions: |
Drug: Acute (1 hour) Sildenafil; Drug: Sub-Chronic (4 weeks) Sildenafil; Drug: Placebo |
| Outcome Measures: |
Exercise Capacity; Flow-Mediated Dilation (FMD); Arterial Stiffness Evaluation (PWV); Physio Flow |
|
| 16 |
Recruiting
|
"As Required" Oral Sildenafil in Raynaud's Phenomenon
| Condition: |
Raynaud's Phenomenon |
| Interventions: |
Drug: Sildenafil 40 mg; Drug: Sildenafil 80 mg; Drug: Placebo |
| Outcome Measures: |
Mean change in the Raynaud's Condition Score (RCS) during treatment, as compared to placebo.; Frequency of RP: number of RP attacks during treatment, as compared to placebo.; Patients' preference: comparison between the number of patients favoring a treatment to another.; Pain associated with RP: Mean change in the Raynaud's pain score during treatment, as compared to placebo.; Frequency and severity of adverse drug events during treatment, as compared to placebo; Microvascular reactivity: index of skin perfusion in response to local/regional cooling after a single dose of sildenafil, as compared to placebo (laboratory experiments) |
|
| 17 |
Recruiting
|
Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension
| Condition: |
Pulmonary Hypertension |
| Intervention: |
Drug: Sildenafil 20mg oral vs Sildenafil 10mg intravenous |
| Outcome Measure: |
Effectiveness |
|
| 18 |
Recruiting
|
Sildenafil Citrate Before Surgery in Improving Kidney Function in Patients With Kidney Cancer
| Condition: |
Kidney Tumor |
| Interventions: |
Drug: sildenafil citrate; Other: placebo; Procedure: therapeutic conventional surgery |
| Outcome Measures: |
Accrual rate; Retention rate; Participation rate; Change in GFR; Change in proteinuria; Estimated blood loss; Hemoglobin concentration; Changes in blood pressure measurements; Vasopressor support requirements during the operative procedure; Intravenous fluid requirements during the operative procedure; Overall complication rates; Preliminary effect size of sildenafil citrate on change in GFR |
|
| 19 |
Unknown †
|
On Demand Versus Daily Sildenafil for Patients Undergoing Radical Prostatectomy
| Condition: |
Erectile Dysfunction |
| Intervention: |
Drug: Sildenafil |
| Outcome Measures: |
Proportion of patients with an Erectile Function domain score of International Index of Erectile Function ( IIEF) => 22 at the end of the wash-out period (44 wks after surgery); Proportion of patients with an Erectile Function domain score of IIEF => 22 at the end of the study (52 wks after surgery); IIEF - Domain Scores for: Erection Hardness Score (1-4) Intercourse success rates defined by the Sexual Encounter Profile (SEP) questionnaire (questions 2 and 3) Safety Endpoints: Adverse event summarized Global assessment questions |
|
| 20 |
Not yet recruiting
|
Growth Hormone or Sildenafil as Therapies for Fatigue in Mild-Traumatic-brain-injury (MTBI)
| Condition: |
Traumatic Brain Injury |
| Interventions: |
Drug: Growth Hormone; Drug: Sildenafil; Drug: Placebo |
| Outcome Measures: |
Perceptual fatigue as measured weekly using the Brief Fatigue Inventory; Performance fatigue as measured by using hand and leg dynamometry. |
|
